Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

31
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
31
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

21
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

23
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
23
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

189
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
189
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

269
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
269

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same author

The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.

Molecular oncology·2026
Same author

Potential impact on cholesterol goal achievement and predicted cardiovascular risk by the addition of ezetimibe and bempedoic acid on top of statins: a simulation from the SANTORINI study.

American journal of preventive cardiology·2026
Same author

Angiopoietin-like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride-rich lipoproteins in humans.

Journal of internal medicine·2026
Same author

Bempedoic acid for prevention of atherosclerotic cardiovascular disease: from trials to clinical practice.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2026
Same author

Targeting triglycerides for cardiovascular risk reduction.

Internal and emergency medicine·2026
Same journal

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Current opinion in lipidology·2026
Same journal

Premature atherosclerotic cardiovascular disease in the MENA region: economic impact, barriers to care, and policy recommendations for an escalating crisis.

Current opinion in lipidology·2026
Same journal

The role of metabolic profiling and dietary intervention in the early diagnosis and prevention of atherosclerosis.

Current opinion in lipidology·2026
Same journal

A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?

Current opinion in lipidology·2026
Same journal

Inflammation and atherosclerotic cardiovascular disease: where do we go from here?

Current opinion in lipidology·2026
Same journal

HDL and ASCVD: is high HDL-C protective, harmful, or simply misleading?

Current opinion in lipidology·2026
See all related articles

Related Experiment Video

Updated: Aug 26, 2025

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
10:59

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases

Published on: November 18, 2013

18.3K

Recent Apolipoprotein CIII trials.

Daniele Tramontano1, Simone Bini, Laura D'Erasmo

  • 1Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

Current Opinion in Lipidology
|October 7, 2022
PubMed
Summary
This summary is machine-generated.

Pharmacological inhibition of Apolipoprotein CIII (ApoCIII) offers a new approach to managing hypertriglyceridemia. Targeting ApoCIII effectively reduces triglyceride-rich lipoproteins, potentially lowering cardiovascular risk.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Related Experiment Videos

Last Updated: Aug 26, 2025

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
10:59

Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases

Published on: November 18, 2013

18.3K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.4K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.4K

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Pharmacology

Background:

  • Apolipoprotein CIII (ApoCIII) is a key regulator of triglyceride-rich lipoprotein (TRL) metabolism.
  • Elevated ApoCIII levels are implicated in hypertriglyceridemia and atherosclerosis.
  • ApoCIII represents a promising therapeutic target for cardiovascular risk reduction.

Approach:

  • This review examines the molecular functions of ApoCIII in lipoprotein metabolism.
  • It assesses the lipid-lowering efficacy of ApoCIII inhibition through clinical trial data.
  • The review discusses future prospects for ApoCIII-targeted therapies.

Key Points:

  • Volanesorsen, an antisense oligonucleotide targeting ApoCIII mRNA, demonstrates significant lipid-lowering potential.
  • Pharmacological inhibition of ApoCIII effectively reduces plasma TRL levels.
  • ApoCIII inhibition is a developing strategy for managing hypertriglyceridemia and associated cardiovascular risks.

Conclusions:

  • ApoCIII inhibition is a viable therapeutic strategy for patients with hypertriglyceridemia.
  • Targeting ApoCIII offers a novel pathway to mitigate cardiovascular risk.
  • Further research into ApoCIII inhibition holds promise for advanced lipid management.